Activity of the Janus kinase inhibitor ruxolitinib in chronic lymphocytic leukemia: results of a phase II trial.

ABSTRACT:

SUBMITTER: Spaner DE 

PROVIDER: S-EPMC5004376 | biostudies-literature | 2016 May

REPOSITORIES: biostudies-literature